|
|
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.South Korea |
First Approval Date29 Jul 2025 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.South Korea |
First Approval Date13 Dec 2024 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.South Korea |
First Approval Date23 Jun 2021 |
/ Not yet recruitingNot Applicable Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Aronia Extract Powder (ABF®) on Antioxidant Capacity
/ RecruitingNot Applicable Efficacy and Safety of ABF on Blood Flow Improvement; A 12 week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
/ Not yet recruitingNot Applicable Double-blind, randomized, placebo-controlled intervention study to evaluate the antioxidant effects and safety of aronia (ABF, Aronia Bioactive Fraction) in healthy voluenteers.
100 Clinical Results associated with JBKLAB Co. Ltd.
0 Patents (Medical) associated with JBKLAB Co. Ltd.
100 Deals associated with JBKLAB Co. Ltd.
100 Translational Medicine associated with JBKLAB Co. Ltd.